Cefcapene pivoxil | Antibiotic/Gasdermin D inhibitor

Available Options

Size:PriceQuantity 
20 mg$35.00
100mg$75.00
Request Quote / Bulk / Custom Size
Product Inquiry

Cefcapene pivoxil (147816-24-8) is a pivalate ester prodrug form of the third generation cephalosporin Cefcapene. Displays broad-spectrum antibacterial activity against both Gram-negative and -positive bacteria including S. aureus.1 Cefcapene pivoxil potently suppresses gasdermin D-mediated pyroptosis via targeting of the oligomerization interface I.2 Active in vivo in a mouse model of sepsis. Cefcapene pivoxil acts synergistically with another gasdermin D inhibitor, SCR-1481B1 (Cat #10-3971), and a PD-L1 antibody to significantly enhance the antitumor activity of anti-PD-L1 therapy.

References/Citations:

  1. Ishikura et al. (1994), Synthesis and Structure-Activity Relationships of 7ß-[(Z)-2-(2-Aminothiazol-4-yl)-3-(Substituted)-2-Propenoylamino]-3-Cephems with C-3 Substitutions; J. Antibiotics. 47 466
  2. Hu et al. (2024), Identification of two repurposed drugs targeting GSDMD oligomerization interface I to block pyroptosis; Cell Chem. Biol. 31 P2024
147816-24-8, cefcapene, cefcapene pivoxil, CEfcapene pivoxil supplier, gasdermin d inhibitor
Alternate Name:
S-1108

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Cefcapene pivoxil (147816-24-8) is a pivalate ester prodrug form of the third generation cephalosporin Cefcapene. Displays broad-spectrum antibacterial activity against both Gram-negative and -positive bacteria including S. aureus.1 Cefcapene pivoxil potently suppresses gasdermin D-mediated pyroptosis via targeting of the oligomerization interface I.2 Active in vivo in a mouse model of sepsis. Cefcapene pivoxil acts synergistically with another gasdermin D inhibitor, SCR-1481B1 (Cat #10-3971), and a PD-L1 antibody to significantly enhance the antitumor activity of anti-PD-L1 therapy.

References/Citations:

  1. Ishikura et al. (1994), Synthesis and Structure-Activity Relationships of 7ß-[(Z)-2-(2-Aminothiazol-4-yl)-3-(Substituted)-2-Propenoylamino]-3-Cephems with C-3 Substitutions; J. Antibiotics. 47 466
  2. Hu et al. (2024), Identification of two repurposed drugs targeting GSDMD oligomerization interface I to block pyroptosis; Cell Chem. Biol. 31 P2024